(
Enrollment of adult patients started at the
Low dropout rate maintained
As reported in
Peter Nordkild, CEO: "Our work with the highly experienced teams at Bispebjerg and Herlev University Hospitals is progressing very positively. I'd like to thank the two teams for their tremendous expertise in ensuring a smooth study with highly motivated patients. We look forward to sharing our topline results."
About Tourette: the unmet need
The unmet need for a safe and effective treatment is significant. A new 2022 study by the
The majority of Tourette cases occur in children between 4 - 12 year's old, for some patients it persists into adulthood. Current treatments like haloperidol (Haldol) can involve extremely severe side effects. 44% of parents feel that current Tourette treatments fail to adequately control their child's symptoms, and 29% of children have tried five or more different medications (2).
Sepranolone: a new approach to Tourette
If full clinical development and regulatory approval is successful, Sepranolone will be the first endogenous, neuroendocrinological compound used to treat Tourette - representing an entirely new treatment modality with no serious side effects. Sepranolone is highly selective and has been designed to target and modulate the effects of allopregnanolone - a powerful neurosteroid in the exacerbation of tics - with no off-target Central Nervous System side effects.
Allopregnanolone is also implicated in a wide range of other stress and compulsion disorders. Sepranolone is
- https://news.cision.com/asarina-pharma/r/asarina-pharma-ab--new-us-cdc-study-suggests-prevalence-of-tourette-significantly-higher-than-previo,c3625977
-
2018, the
Tourette Association of America ,Impact Survey
For further information, please contact:
Peter Nordkild, CEO
Phone: +45 25 47 16 46
E-mail: peter.nordkild@asarinapharma.com
ABOUT
We are a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive Compulsive Disorder that still lack safe, efficacious pharmaceutical treatments.
The information above was provided by
https://news.cision.com/asarina-pharma/r/patient-recruitment-completed-in-landmark-tourette-syndrome-study,c3648317
https://mb.cision.com/Main/17069/3648317/1638666.pdf
(c) 2022 Cision. All rights reserved., source